This document discusses generic drugs for treating hepatitis C. It notes that generic drugs contain the same active ingredients as brand name drugs but are usually launched after patents expire. While poorest countries are not subject to intellectual property laws leading to higher generic drug prices, factors like production costs are considered in pricing. Studies found generic sofosbuvir, ledipasvir and daclatasvir were safe and effective. The document advises being honest with patients about potential risks and benefits of generics and arguing for better accessibility of hepatitis C treatments.